Abstract:BACKGROUND:Two groups of gain-of-function mutations in sodium channel NaV1.7, which are expressed in dorsal root ganglion (DRG) neurons, produce two clinically-distinct pain syndromes - inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEPD). IEM is characterized by intermittent burning pain and skin redness in the feet or hands, triggered by warmth or mild exercise, while PEPD is characterized by episodes of rectal, ocular and mandibular pain accompanied with skin flushing, triggered by bowel movement and perianal stimulation. Most of the IEM mutations are located within channel domains I and II, while most of the PEPD mutations are located within domains III and IV. The structural dichotomy parallels the biophysical effects of the two types of mutations, with IEM mutations shifting voltage-dependence of NaV1.7 activation in a hyperpolarized direction, and PEPD mutations shifting fast-inactivation of NaV1.7 in a depolarized direction. While four IEM and four PEPD mutations are located within cytoplasmic linkers joining segments 4 and 5 (S4-S5 linkers) in the different domains (IEM: domains I and II; PEPD: domains III and IV), no S4-S5 linker has been reported to house both IEM and PEPD mutations thus far.RESULTS:We have identified a new IEM mutation P1308L within the C-terminus of the DIII/S4-S5 linker of NaV1.7, ten amino acids from a known PEPD mutation V1298F which is located within the N-terminus of this linker. We used voltage-clamp to compare the biophysical properties of the two mutant channels and current-clamp to study their effects on DRG neuron excitability. We confirm that P1308L and V1298F behave as prototypical IEM and PEPD mutations, respectively. We also show that DRG neurons expressing either P1308L or V1298F become hyperexcitable, compared to DRG neurons expressing wild-type channels.CONCLUSIONS:Our results provide evidence for differential roles of the DIII/S4-S5 linker N- and C-termini in channel inactivation and activation, and demonstrate the cellular basis for pain in patients carrying these mutations.

Genetic, Electrophysiological, and Pathological Studies on Patients with SCN9A-related Pain Disorders.

A Novel SCN9A Gene Variant Identified in a Chinese Girl with Paroxysmal Extreme Pain Disorder (PEPD): a Rare Case Report.

Two Novel<i>SCN9A</i>Gene Heterozygous Mutations May Cause Partial Deletion of Pain Perception

Variable epilepsy phenotypes associated with heterozygous mutation in the SCN9A gene: report of two cases

Exonic mutations in SCN9A (NaV1.7) are found in a minority of patients with erythromelalgia

SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes

Gain-of-Function mutations in SCN11A cause familial episodic pain

Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations

Pain perception is altered by a nucleotide polymorphism in SCN9A

Novel SCN9A Missense Mutations Contribute to Congenital Insensitivity to Pain: Unexpected Correlation Between Electrophysiological Characterization and Clinical Phenotype

Familial episodic limb pain in kindreds with novel Nav1.9 mutations

Mutations at Opposite Ends of the DIII/S4-S5 Linker of Sodium Channel NaV1.7 Produce Distinct Pain Disorders

Progress in the Study of Voltage-Gated Sodium Channel Nav1.7 in Pain

Genetic Analysis of SCN11A, SCN10A, and SCN9A in Familial Episodic Pain Syndrome (FEPS) in Japan and Proposal of Clinical Diagnostic Criteria

Mexiletine-responsive Erythromelalgia Due To A New NaV1.7 Mutation Showing Use-dependent Block

A SCN10A SNP Biases Human Pain Sensitivity.

A New Na(V)1.7 Mutation in an Erythromelalgia Patient

Gain-Of-Function Na(V)1.8 Mutations in Painful Neuropathy

Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia.

Gain of function Naν1.7 mutations in idiopathic small fiber neuropathy.

Mexiletine-responsive erythromelalgia due to a new Nav1.7 mutation showing use-dependent current fall-off